Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans

Aim/hypothesis Leptin has been shown to regulate angiogenesis in animal and in vitro studies by upregulating the production of several pro-angiogenic factors, but its role in regulating angiogenesis has never been studied in humans. Methods The potential angiogenic effect of two doses of metreleptin...

Full description

Saved in:
Bibliographic Details
Published in:Diabetologia 2011-09, Vol.54 (9), p.2358-2367
Main Authors: Aronis, K. N., Diakopoulos, K. N., Fiorenza, C. G., Chamberland, J. P., Mantzoros, C. S.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Angiogenesis
Angiogenesis Inducing Agents - blood
Angiopoietin-1 - blood
Biological and medical sciences
Body fat
Diabetes
Diabetes. Impaired glucose tolerance
Dose-Response Relationship, Drug
Endocrine pancreas. Apud cells (diseases)
Endocrinology
Endocrinopathies
Endothelial Growth Factors - blood
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
Health care
Human Physiology
Humans
Injections, Subcutaneous
Internal Medicine
Leptin - administration & dosage
Leptin - analogs & derivatives
Leptin - pharmacology
Male
Matrix Metalloproteinase 8 - blood
Matrix Metalloproteinase 9 - blood
Medical sciences
Medicine
Medicine & Public Health
Metabolic Diseases
Neovascularization, Physiologic - drug effects
Physiology
Platelet-Derived Growth Factor - metabolism
Ribonuclease, Pancreatic - blood
Thinness - blood
Vascular endothelial growth factor
Vascular Endothelial Growth Factor A - blood
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aim/hypothesis Leptin has been shown to regulate angiogenesis in animal and in vitro studies by upregulating the production of several pro-angiogenic factors, but its role in regulating angiogenesis has never been studied in humans. Methods The potential angiogenic effect of two doses of metreleptin (50 and 100 ng/ml) was evaluated in vitro, using a novel three-dimensional angiogenesis assay. Fifteen healthy, normoleptinaemic volunteers were administered both a physiological (0.1 mg/kg) and a pharmacological (0.3 mg/kg) single dose of metreleptin, in vivo, on two different inpatient admissions separated by 1–12 weeks. Serum was collected at 0, 6, 12 and 24 h after metreleptin administration. Twenty lean women, with leptin levels
ISSN:0012-186X
1432-0428
DOI:10.1007/s00125-011-2201-x